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Abstract
 
To assess directly the role of protein kinase C (PKC)
 
 
 
 in the immune system, we generated
mice that carried a homozygous disruption of the PKC
 
 
 
 locus. PKC
 
 
 
 
 
/
 
 
 
 animals appeared
normal and were generally healthy, although female mice frequently developed a bacterial in-
fection of the uterus. Macrophages from PKC
 
 
 
 
 
/
 
 
 
 animals demonstrated a severely attenuated
response to lipopolysaccharide (LPS) and interferon (IFN)
 
 
 
, characterized by a dramatic re-
duction in the generation of NO, tumor necrosis factor (TNF)-
 
 
 
, and interleukin (IL)-1
 
 
 
.
Further analysis revealed that LPS-stimulated macrophages from PKC
 
 
 
 
 
/
 
 
 
 mice were defi-
cient in the induction of nitric oxide synthase (NOS)-2, demonstrating a decrease in the acti-
vation of I
 
 
 
B kinase, a reduction in I
 
 
 
B degradation, and a decrease in nuclear factor (NF)
 
 
 
B
nuclear translocation. After intravenous administration of Gram-negative or Gram-positive
bacteria, PKC
 
 
 
 
 
/
 
 
 
 mice demonstrated a significantly decreased period of survival. This study
provides direct evidence that PKC
 
 
 
 is critically involved at an early stage of LPS-mediated
signaling in activated macrophages. Furthermore, we demonstrate that in the absence of
PKC
 
 
 
, host defense against bacterial infection is severely compromised, resulting in an in-
creased incidence of mortality.
Key words: nitric oxide • protein kinase C • nitric oxide synthase • macrophage activation • 
bacterial infection
 
Introduction
 
The protein kinase C (PKC)
 
*
 
 family of serine/threonine
kinases consists of at least 11 closely related isoenzymes that
can be subdivided into three groups (1). The classical iso-
types are calcium and diacylglycerol dependent, and in-
clude PKC
 
 
 
, PKC
 
 
 
I and 
 
 
 
II, and PKC
 
 
 
. The novel iso-
types are also diacylglycerol dependent, but are calcium
independent. These include PKC
 
 
 
, PKC
 
 
 
, PKC
 
 
 
, and
PKC
 
 
 
 (2). The atypical isotypes, comprising of PKC
 
 
 
 and
PKC
 
 
 
/
 
 
 
, are nonresponsive to diacylglycerol. In any one
tissue several isoenzymes can be expressed, and redundancy
of function has often hampered the identification of defini-
tive roles for individual family members. Nevertheless, in
recent years, mice deficient for PKC
 
 
 
 (both 
 
 
 
I and 
 
 
 
II),
PKC
 
 
 
, PKC
 
 
 
, and PKC
 
 
 
 have all been generated, and the
analysis of these animals has increasingly highlighted the es-
sential nonredundant roles for PKC isoenzymes in many
systems (3–6).
Several of the reported phenotypes for PKC mutant
mice have identified a role for a specific isoenzyme in the
cells of the immune system. For example, mice deficient
for PKC 
 
 
 
I and 
 
 
 
II have a marked immunodeficiency that
is characterized by an attenuated humoral immune re-
sponse specifically associated with an impairment of signal-
ing through the B cell receptor (4). In contrast, mice defi-
cient for PKC
 
 
 
 have a defect in T cell receptor signaling,
which results in a severe decrease in nuclear factor (NF)
 
 
 
B
activation and mature T cell proliferation (6).
A number of in vitro and ex vivo studies have also impli-
cated a role for PKC
 
 
 
 in the regulation of the immune sys-
tem. In immature thymocytes, it was suggested that PKC
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 ERK, extracellular signal–regulated ki-
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Macrophage Activation in PKC
 
 
 
 
 
/
 
 
 
 Mice
 
was involved in glucocorticoid-induced apoptosis (7),
while in mature T cell lines, PKC
 
 
 
 activation was impli-
cated in signaling through the high-affinity IL-2 receptor
(8). Much evidence also exists to suggest that PKC
 
 
 
 could
be an important mediator of macrophage function. For ex-
ample, it was demonstrated using several complementary
experimental approaches that the macrophage-specific in-
hibition of PKC
 
 
 
 was partly responsible for the antiinflam-
matory action of IL-4 (9). In addition, the expression of
PKC
 
 
 
 was shown to be sufficient for NO production in
the RAW 264.7 macrophage cell line (10), while a number
of studies have suggested that the activation of PKC
 
 
 
 is a
critical event in the signaling response of primary macro-
phages to either LPS (11, 12), or GM-CSF (13). Further-
more, it was recently demonstrated that PKC
 
 
 
 is required
for the induction of mitogen-activated protein kinase phos-
phatase-1 in LPS-stimulated macrophages (14), and that
macrophage phagocytosis is dependent on the activation of
a nPKC, specifically PKC
 
 
 
 (15).
To address directly whether PKC
 
 
 
 has a role in the func-
tion of the various cell types of the immune system, we
generated and characterized mice with a targeted disruption
of the PKC
 
 
 
 gene. Thymocyte apoptosis, T cell prolifera-
tion, and B cell function were all comparable to that ob-
served in control littermates. However, even though circu-
lating monocytes were present at wild-type levels, and
maturation and homing of these cells appeared normal,
elicited peritoneal macrophages generated significantly
lower levels of NO, TNF
 
 
 
, and IL-1
 
 
 
 in response to LPS
and IFN
 
 
 
 stimulation. We demonstrate that LPS-treated
macrophages from PKC
 
 
 
 
 
/
 
 
 
 mice failed to induce nitric
oxide synthase-2 (NOS-2) expression and showed a signifi-
cant reduction in the activation of both I
 
 
 
B kinase (IKK)
and NF
 
 
 
B. The p44 and p42 extracellular signal–regulated
kinase (ERK) kinases and the p38 mitogen-activated pro-
tein (MAP) kinases were also activated to a considerably
lesser extent in PKC
 
 
 
 
 
/
 
 
 
 cells. In addition, we demonstrate
that PKC
 
 
 
 
 
/
 
 
 
 mice displayed a significant increase in sensi-
tivity and mortality in response to either an intravenous
Gram-negative or Gram-positive bacterial infection. Taken
together, these data implicate PKC
 
 
 
 as a critical component
of the LPS signaling cascade in activated macrophages, and
highlights the importance of this gene in mounting an ef-
fective immune response to various bacterial pathogens.
 
Materials and Methods
 
Chemicals.
 
Reagents were from Sigma-Aldrich, Roche, and
Merck. For cytokine assays Biotrak kits were from Amersham
Pharmacia Biotech. Cytokines were from Roche. LPS was from
 
Salmonella typhimurium 
 
(Sigma-Aldrich). Serum and other cell
culture reagents were from BioWhittaker. Antibodies were
from Santa Cruz Biotechnology, Inc. and from New England
Biolabs, Inc.
 
Generation of PKC
 
 
 
 
 
/
 
 
 
 Mice.
 
A 9.3-kb EcoRI fragment con-
taining the first exon of the PKC
 
 
 
 gene was isolated from a mu-
rine 129/Sv genomic DNA library (gift from T. Rabbitts, Labo-
ratory of Molecular Biology, Cambridge). A targeting vector was
generated by introducing a positive selectable cassette into the
PstI site of exon 1. This cassette contains stop codons in all three
frames, an independent ribosomal entry site (IRES) followed by
the 
 
LacZ
 
 gene with an SV40 polyadenylation sequence, and a
neomycin phosphotransferase gene (MC1Neo poly(A); gift from
A. Smith, Centre for Genome Research, Edinburgh, UK). Cor-
rectly targeted GK129 ES cells (see Fig. 1 for Southern blot de-
tails) were injected into C57BL/6 blastocysts. Chimeric mice
were bred to C57BL/6 mice in specific pathogen-free (SPF) con-
ditions to generate PKC
 
 
 
 homozygous mutant animals. PKC
 
 
 
 
 
/
 
 
 
and PKC
 
 
 
 
 
/
 
 
 
 mice were maintained on a mixed C57Bl/6 
 
 
 
129/Sv genetic background and were genotyped by Southern
blot (Fig. 1, A and B) or PCR analysis of tail DNA (data not
shown). Mice were fed ad libitum with a standard diet (Panlab)
and kept under a light and dark cycle of 12 h (lights on at 8 a.m.).
 
Preparation of Peritoneal Macrophages.
 
4 d before use, mice
were injected intraperitoneally with 1 ml of sterile 3% (wt/vol)
thioglycollate (16). After sacrificing the animals, the peritoneal
cavity was flushed with 10 ml of sterile RPMI 1640. The perito-
neal cell suspension was carefully aspirated avoiding hemorrhage
and kept at 4
 
 
 
C to prevent the adhesion of the macrophages to
plastic. Cells were recovered by centrifugation at 200 
 
g
 
 for 10
min and washed twice with 25 ml of ice-cold PBS. Cells were
seeded at 10
 
6
 
/cm
 
2
 
 in RPMI 1640 supplemented with 10% heat-
inactivated FCS and 50 
 
 
 
g/ml of gentamicin, penicillin, and
streptomycin. After incubation for 1 h at 37
 
 
 
C in a 5% CO
 
2
 
 at-
mosphere, nonadherent cells were removed by extensive washing
with PBS. Experiments were performed in phenol red-free
RPMI 1640 supplemented with 0.5 mM arginine and 10% heat-
inactivated FCS plus antibiotics and agonists as indicated in the
figures and legends (16). For in vivo experiments, animals were
injected intraperitoneally with 0.5 ml of a solution containing
LPS from 
 
S. typhimurium
 
 and D-galactosamine (17, 18). An 
 
Escher-
ichia coli
 
 (strain ATCC 25922) or 
 
Staphylococcus aureus
 
 (strain
ATCC 6538P) suspension in PBS was quantified and adminis-
tered (0.5 ml) through the tail vein.
 
Flow Cytometric Analysis.
 
Cells were stained with PE-labeled
antimurine CD11b (clone M1/70) and FITC-labeled anti-CD14
(clone rmC5–3) from BD PharMingen and analyzed on a FAC-
Scan™ cytometer (Becton Dickinson) equipped with a 25-mW
argon laser. Analysis of apoptotic cells was performed by propid-
ium iodide staining, following a previous protocol (19, 20). The
quantification of the percentage of apoptotic cells was done using
a dot plot of the forward scatter against the phosphatidylinositol
fluorescence. Cell sorting and analysis of viable and apoptotic
populations was performed to confirm the criteria of gating (20).
 
Preparation of Blood Samples for Cytokine and PGE
 
2
 
 Assay.
 
Blood was collected from the tail vein or by cardiac puncture at
the indicated times and the levels of TNF
 
 
 
, IL-1
 
 
 
, and PGE
 
2
 
were assayed using an enzyme immunoassay kit, following the
suppliers recommendations (Biotrak; Amersham Pharmacia Bio-
tech).
 
Determination of NO Synthesis.
 
NO release was determined
spectrophotometrically by the accumulation of nitrite and nitrate
in the medium (phenol red-free). Nitrate was reduced to nitrite as
described (16). Nitrite levels were determined with Griess re-
agent. Results are expressed as the amount of nitrite and nitrate
released per mg of cell protein.
 
Preparation of Cell Extracts.
 
Adhered macrophages were
washed twice with ice-cold PBS and the plates (6-cm diameter)
were filled with 0.4 ml of buffer A (20 mM Tris-HCl, pH 7.8; 5
mM MgCl
 
2
 
, 10 mM KCl, 0.5 mM EGTA, 1 mM phenylmethyl-
sulfonyl fluoride, 0.5 mM dithiothreitol, and 10 
 
 
 
M leupeptin).
The cells were scraped off the dishes using a rubber policeman 
1233 Castrillo et al.
and mixed with one volume of a 1% Nonidet P-40 solution. The
tubes were gently vortexed for 15 s and nuclei were sedimented
by centrifugation at 8,000 g for 15 s. Aliquots of the supernatant
were stored at  80 C (cytosolic extracts), and the nuclear pellets
were resuspended in 100  l of buffer A supplemented with 0.4 M
KCl. Nuclear proteins were extracted by centrifugation at 13,000 g
for 15 min and aliquots of the supernatant were stored at  80 C
(16). Proteins were measured using the Bio-Rad Laboratories de-
tergent-compatible protein reagent. All steps of cell fractionation
were performed at 4 C.
Measurement of IKK2 Activity. Cells (107) were homogenized
in buffer A and centrifuged at maximal speed for 10 min in a mi-
crocentrifuge. The supernatant (1 ml) was precleared and IKK2
was immunoprecipitated with 1  g of anti-IKK2 Ab (21). After
five washes of the immunoprecipitate with buffer A, the pellet
was resuspended in kinase buffer (20 mM HEPES, pH 7.4; 0.1
mM EDTA, 100 mM NaCl, 1 mM DTT, 0.5 mM PMSF, 2  g/
ml aprotinin, 10  g/ml leupeptin, 2  g/ml TLCK, 5 mM NaF,
1 mM NaVO4, 10 mM Na2MoO4 and 10 nM okadaic acid). Ki-
nase activity was assayed in 100  l of buffer A containing 100 ng
of immunoprecipitation, 50  M [ -32P]ATP (0.5  Ci), and us-
ing as substrate 100 ng of GST-I B  (amino acids 1–54). Con-
trols with the corresponding S32A and S36A mutated protein
were unable to be phosphorylated under these conditions (data
not shown). Aliquots of the reaction were stopped at various time
points with 1 ml of ice-cold buffer A supplemented with 5 mM
EDTA. The linearity of the kinase reaction was confirmed over a
period of 30 min.
Electrophoretic Mobility Shift Assays. An oligonucleotide corre-
sponding to the proximal  B motif of the murine NOS-2
promoter (22, 23) 5 -CCAACTGGGGACTCTCCCTTTGG-
GAACA-3 , and one corresponding to the PPAR  binding site
of the promoter of acyl-CoA oxidase (24) 5 -CGAACGTGAC-
CTTTGTCCTCCCCTTTTGCTCGATC-3 , were annealed
with complementary sequence (50 ng) and labeled with Klenow
enzyme in the presence of 50  Ci of [ -32P]dCTP plus unlabeled
dNTPs to a final volume of 50  l. The probes were precipitated
with ethanol and extracted with phenol/chloroform. DNA bind-
ing assays of nuclear extracts were performed by incubating for 30
min at 4 C, 5   104 dpm of the DNA probe with 5  g of nu-
clear protein, 1  g/ml of poly(dI·dC), 5% glycerol, 1 mM
EDTA, 100 mM KCl, 5 mM MgCl2, 1 mM dithiothreitol, and
10 mM Tris-HCl, pH 7.8, in a final volume of 20  l. The incu-
bation mixture was applied to a 6% polyacrylamide gel that had
been electrophoresed previously for 30 min at 100 V. Gels were
electrophoresed at 0.8 volts/cm2 in 45 mM Tris-borate, followed
by vacuum-transference to 3MM Whatman paper and quantifica-
tion of the band intensities in an autoradiograph (Fuji Bas 1000).
Analysis of competition with unlabeled oligonucleotides was per-
formed using a 20-fold excess of double stranded DNA in the
binding reaction, and adding the nuclear extracts as the last step in
the binding assay. Supershift assays were performed after addition
of antibodies (0.5  g) to the binding reaction and incubation for
1 h at 4 C (22).
Western Blot Analysis. Cytosolic and nuclear extracts were
obtained as described previously (22). Samples containing equal
amounts of protein (30  g and 10  g per lane of cytosolic and
nuclear extracts, respectively) were boiled in 250 mM Tris-HCl,
pH 6.8, 2% SDS, 10% glycerol, 2%  -mercaptoethanol, and size-
separated in 10% SDS-PAGE. The gels were processed as recom-
mended by the supplier of the antibodies against various murine
antigens (NOS-2, I B , phospho(S32)I B , p38 and p42/p44
MAP kinases, p50, and p65; from Santa Cruz Laboratories or
New England Biolabs, Inc.) and after blotting onto a polyvinyli-
dine difluoride (PVDF) membrane, proteins were revealed fol-
lowing the enhanced chemoluminescence (ECL) technique
(Amersham Pharmacia Biotech). Different exposure times of the
films were used to ensure that bands were not saturated. Quanti-
fication of the films was performed by laser densitometry (Mo-
lecular Dynamics). Westerns for PKC were as described previ-
ously (see reference 10).
RNA Extraction and Analysis. Total RNA (2–4   106 cells)
was extracted following the guanidinium thiocyanate method
(Trizol; GIBCO BRL). For Northern blot analysis equal amounts
of RNA were denatured and size-separated by electrophoresis in
a 0.9% agarose gel containing 2% formaldehyde and MOPS buf-
fering system as described previously (22). The RNA was trans-
ferred to Nytran membranes (NY 13-N; Schleicher & Schuell)
with 10  SSC (1.5 mM NaCl, 0.3 mM sodium citrate, pH 7.4).
An 817-bp fragment (nucleotides 1 to 817) from the cDNA of
murine NOS-2 was labeled as a probe with the Rediprime kit
(Amersham Pharmacia Biotech). The intensity of the bands was
quantified in a Fuji BAS1000 autoradiograph using hybridization
with a ribosomal 18S probe as an internal control. For reverse
transcription (RT)-PCR, cDNA was generated from 10  g of
total RNA using the SMART cDNA synthesis technique
(CLONTECH Laboratories, Inc.). A standard 30 cycle PCR was
then performed on one hundredth of the starting sample using
the following primers; PKC (F) 5 -GCCAAAGTGCTGGCT-
GACCTTGG-3 , PKC (R) 5 -CGGCATAGAACCGAGAAC-
GAGGC-3 ,  -act(F) 5 -TGCCTGACGGCCAGGTCATCA-3 ,
 -act(R) 5 -CGGACTCGTCATACTCCTGC-3 . An anneal-
ing temperature of 62 C was used for both PCRs (Advantage 2;
CLONTECH Laboratories, Inc.).
Statistical Analysis. The data shown are the means   SEM of
the number of experiments or animals indicated. The product
limit of the cumulative survival (Kaplan-Meier) was calculated
with the Log-rank test for all survival data using the SPSS 10.0
software. Statistical significance was estimated with analysis of
variance (ANOVA) and Student’s t test for unpaired observa-
tions, using commercially available software (SPSS). A P value of
less than 0.05 was considered significant.
Results
Generation of Mice Deficient for PKC . Several recent
studies have strongly implicated PKC, and more specifically
PKC , in various aspects of the maturation and function of
the immune system. To address these issues directly, mice
deficient for PKC  were generated by inserting a LacZ/
Neo sequence into the first exon of the PKC  gene (Fig. 1
A). ES cells (data not shown) and mice heterozygous or
homozygous for the PKC  mutation were assessed by
Southern blot analysis for a correct targeting event (Fig. 1,
A and B). RT-PCR (Fig. 1 C), Northern blot analysis
(data not shown), and Western blot analysis confirmed that
PKC  mRNA and protein were absent at this level of de-
tection, whereas protein levels for other PKC isoenzymes
remained unaltered (Fig. 1 D).
After heterozygous mating, PKC  /  mice were born
at the expected Mendelian frequency, with life expect-
ancy no different to wild-type littermates. PKC -deficient
animals were, however, 10–15% smaller than controls,1234 Macrophage Activation in PKC  /  Mice
and did not lay down a large amount of adipose tissue
with increasing age.
Various aspects of the immune system were investigated
in PKC  /  mice. Thymocytes and T cells developed
normally, had an unchanged surface phenotype, and were
present at expected numbers. Thymocyte apoptosis to a
range of stimuli, including dexamethasone, was compara-
ble to wild type. T cell proliferation to anti-CD3  anti-
body or anti-TCR   antibody was marginally reduced to
 80% of controls, although the T cell response to antigen
after a prior immunization was comparable to wild-type
littermates (data not shown). B cells were present at ex-
pected numbers with a normal surface phenotype, and se-
rum Ig levels were similar to controls. Basic blood histol-
ogy and biochemistry revealed no differences between
PKC  /  mice and wild-type littermates (data not
shown).
A problem was observed when breeding with homozy-
gous PKC  /  animals. On average, only one in four fe-
male PKC  /  mice produced a litter, with a second litter
from these animals being very rare. On closer examination
there was no evidence of a pregnancy of any length in non-
litter bearing mothers after a plugging event. On autopsy,
 30% of non-litter bearing female mice presented with
distended fluid-filled uteri. Furthermore, even though au-
toclaved bedding, water, and food were used, a granulo-
cyte/macrophage infiltrate and the presence of copious
Gram-negative bacteria such as E. coli and various strains of
Proteus were detected in the uterine fluid. No obvious de-
formity in uterus structure was observed in healthy
PKC  /  animals (data not shown).
Macrophages from PKC  /  Mice Generate Reduced NO
and Express Lower Levels of NOS-2 mRNA and Protein in Re-
sponse to In Vitro Challenge with LPS. As PKC  /  mice
were succumbing to E. coli–related bacterial infection, it
was hypothesized that their response to Gram-negative
bacteria was somehow compromised. To test this, mac-
rophages were elicited via intraperitoneal thioglycollate in-
jection and their response to in vitro administration of LPS
was assessed measuring nitrite generation as a functional
end point. The number of macrophages obtained from
PKC  /  mice were comparable to littermate controls,
and the percentage of cells expressing cell-surface levels of
both CD14, an integral component of the LPS receptor,
and CD11b was similar (Fig. 2 A). At lower doses of LPS,
below 200 ng/ml, macrophages from PKC  /  mice gen-
erated significantly lower amounts of NO than macro-
phages from control animals (Fig. 2 B). However, at sub-
stantially higher concentrations of LPS, above 500 ng/ml,
a comparable production of NO was detected from both
groups. Macrophages can be activated to a greater degree if
IFN  is allowed to act synergistically with LPS. Using a set
concentration of both LPS and IFN , the generation of
NO over a 36-h period was also demonstrated to be signif-
icantly reduced in macrophages from PKC  /  mice
when compared with macrophages from wild-type con-
trols (Fig. 2 C). It should be noted that IFN  treatment
alone can result in the generation of NO from macro-
phages, although this response is lower and delayed with re-
spect to the response observed with LPS (16). In PKC  / 
animals the generation of NO after in vitro IFN  treat-
ment of elicited macrophages was also reduced in compar-
Figure 1. The generation and characterization of PKC  / 
mice. (A) Schematic representation of the PKC  locus knock-
out strategy, illustrating the insertion of a lacZ/Neo cassette
into the PstI site in the first exon of the PKC  gene. The pre-
dicted EcoRI fragments and probe for Southern blot analysis of
the wild-type and mutant alleles are shown. (B) Southern blot
analysis of homozygous mutant, heterozygous and wild-type
tail DNA from a representative litter. (C) RT-PCR on brain
RNA from two wild-type and two PKC  /  mice. RT-PCR
for  -actin is shown as loading control. (D) Western blot anal-
ysis for PKC family members on brain tissue from PKC  / 
and control mice.1235 Castrillo et al.
ison to wild-type littermates (data not shown). The basis of
this reduced response to IFN  in the PKC  /  mice is
presently unclear. However, studies are underway to assess
the extent of this defect and to characterize the cellular
components involved.
As macrophages are known to generate NO via the up-
regulation of the expression of NOS-2, the protein level of
NOS-2 was assessed in vitro after the activation of thiogly-
collate-elicited macrophages by LPS and IFN . Fig. 3 A
demonstrates that cultured macrophages from PKC  / 
mice displayed a severely reduced level of NOS-2 protein
expression after both 18 and 24 h of stimulation when
compared with wild-type cells. To verify this decrease in
LPS-induced NOS-2 expression, LPS was administered in
vivo via an intraperitoneal injection. After 24 h, macro-
phages were isolated from the peritoneal cavity and again
assayed for NOS-2 protein expression. As shown in Fig. 3
B, the extent of induction of NOS-2 protein in response to
LPS is severely attenuated in macrophages from PKC -
deficient animals. As NOS-2 activity is mainly controlled at
the level of transcription (23), the in vitro expression of
NOS-2 RNA in response to LPS plus IFN  challenge was
determined. Fig. 3 C demonstrates that after such a chal-
lenge NOS-2 RNA levels were significantly decreased in
macrophages from PKC  /  mice when compared with
controls. These data suggest that the reduction in LPS-
induced NO generation in macrophages from PKC  / 
mice is a result of the failure to upregulate the expression of
both NOS-2 RNA and protein.
Macrophages from PKC  /  Mice Release Reduced Levels of
Proinflammatory Mediators in Response to LPS, and Fail to Un-
dergo Activation-induced Apoptosis. In addition to the syn-
thesis of NO, activated macrophages are known to release a
wide range of cytokines and other gene products that pro-
mote an inflammatory response and help to initiate adap-
tive immunity. The production of TNF , IL-1 , and
prostaglandin E2 (PGE2) were therefore analyzed after in
vitro LPS and IFN  stimulation of thioglycollate-elicited
macrophages. Fig. 4, A–C, clearly demonstrates that mac-
Figure 2. Macrophages from PKC  /  mice generate less NO in re-
sponse to LPS challenge. (A) Graphical representation of the percentage
of thioglycollate-elicited peritoneal macrophages that expressed cell-sur-
face CD11b and CD14. (B) Graph showing the release of nitrite into
the culture medium after the activation of thioglycollate-elicited perito-
neal macrophages with increasing concentrations of LPS for 24 h. (C)
Graphical view of nitrate release into the culture medium after the acti-
vation of thioglycollate-elicited peritoneal macrophages with a fixed
concentration of both LPS (200 ng/ml) and IFN  (20 U/ml) for in-
creasing periods of time. Results show the mean   SEM of three exper-
iments. The * denotes P   0.05 for experimental vs. wild-type animals
for the parameters indicated.
Figure 3. Macrophages from PKC  /  mice fail to fully induce NOS-2
expression after LPS activation. (A) Western blot for NOS-2 levels in
thioglycollate-elicited peritoneal macrophages after 18 or 24 h activation
with LPS (200 ng/ml) and IFN  (20 U/ml). (B) Western blot showing
NOS-2 expression in peritoneal macrophages 24 h after an intraperitoneal
in vivo challenge with LPS. (C) NOS-2 mRNA levels in macrophages
after 4 and 6 h activation with LPS and IFN . Loading was normalized by
using a probe for 18S ribosomal RNA as a control.1236 Macrophage Activation in PKC  /  Mice
rophages from PKC  /  mice generated severely attenu-
ated levels of TNF , IL-1 , and PGE2 compared with
macrophages from wild-type animals. The release of these
proinflammatory mediators was also assessed in vivo after
the intraperitoneal administration of LPS after sensitization
with D-galactosamine (17). Serum levels of TNF  and IL-
1  were both significantly reduced in PKC  /  mice
when compared with the levels observed in littermate con-
trols (Fig. 4, D and E).
Macrophages are known to show characteristic apop-
totic cell death at late time points after activation. As an
additional indicator of normal macrophage function, the
extent of activation-induced apoptosis on thioglycollate-
elicited macrophages was analyzed in vitro after 24 h cul-
ture in the presence of either LPS, LPS and IFN , or LPS,
IFN , and 15dPGJ2, apoptotic conditions that have been
characterized previously (20). As shown in Fig. 4 F,  15%
of elicited macrophages from PKC  /  mice undergo
apoptosis in response to any of the three treatments. In
contrast, wild-type macrophages show a level of apoptosis
of over 20% for each stimulation, with over 50% of the
cells undergoing apoptosis in response to the combined
action of LPS, IFN , and 15dPGJ2. Taken together these
results indicate that many mediators of macrophage func-
tion in response to LPS are severely disrupted in mice de-
ficient for PKC .
LPS-activated Macrophages from PKC  /  Mice Show Sig-
nificant Impairment of NF B Activation, and I B Kinase Activ-
ity. Much evidence exists to suggest that the upregulation
of NOS-2 requires the transcription factor NF B (23, 25).
Macrophages are known to express NF B constitutively,
but in resting cells NF B forms an inactive cytoplasmic
complex with I B. On activation, I B is phosphorylated
and degraded, leading to the release of NF B, which trans-
locates to the nucleus as an active transcription factor. To
assess whether the reduction of NOS-2 expression in
PKC  /  mice was due to a decrease in NF B activation,
the presence of active NF B in macrophage nuclear ex-
tracts was analyzed by electrophoretic mobility shift assay
(EMSA) after increasing length of LPS stimulation of
thioglycollate-elicited cells. The distal  B sequences from
the NOS-2 promoter were used to bind the nuclear ex-
tracts. In comparison to the clear binding of NF B
(p50.p65) in wild-type lysates, NF B levels in nuclear ex-
tracts from PKC  /  mice were greatly reduced at all time
points analyzed (Fig. 5 A). Supershift assays were per-
formed to verify the nature of the observed bands (data not
shown). These results suggest that the failure to activate
NF B in PKC  /  macrophages could be responsible for
the low levels of NOS-2 expression observed in response
to LPS stimulation.
The nuclear translocation of NF B results from the
phosphorylation and subsequent degradation of I B. Mac-
rophages from PKC  /  mice demonstrate an impaired
degradation of I B  in response to LPS (Fig. 5 B). Consis-
tent with this observation, a reduction in the phosphoryla-
tion of I B  was detected with a specific anti-P(S32)I B 
Ab in PKC -deficient macrophages treated with MG 132
to inhibit proteasome function (21) and hence I B  deg-
radation (Fig. 5 B). Phosphorylation of I B  is mediated
in part by I B kinase-2 (IKK-2). Therefore, the activity of
IKK-2 in LPS-activated thioglycollate-elicited macro-
phages was assessed after immunoprecipitation of IKK-2
from cytosolic extracts, using a kinase assay with GST-
I B  and [ -32P]ATP as substrates. Phosphorylation of the
GST-I B  substrate by IKK-2 was significantly decreased
in macrophages from PKC  /  mice when compared
with that of controls (Fig. 5 C). Thus, a failure to activate
IKK-2 in LPS-stimulated macrophages could be responsi-
ble for the impaired degradation of I B  and the reduc-
tion in active NF B observed in nuclear extracts from
PKC  /  mice.
Figure 4. The release of
proinflammatory cytokines and
prostaglandin E2 are impaired in
PKC  /  mice. (A–C) Thiogly-
collate-elicited peritoneal mac-
rophages were activated for the
indicated times with 200 ng/ml
of LPS and 20 U/ml of IFN .
The amount of TNF- , IL-1 ,
and PGE2 in the culture me-
dium was then determined. (D–
E) Bar graphs demonstrating the
serum levels of TNF-  (1 h after
injection) and IL-1  (4 h after
injection) after the intraperito-
neal injection of either 5 mg/kg
or 40 mg/kg of LPS. (F) Apop-
tosis of thioglycollate-elicited
peritoneal macrophages 24 h af-
ter activation by LPS (200 ng/
ml), LPS plus IFN  (200 ng/ml
and 20 U/ml, respectively), or
LPS, IFN , and 15dPGJ2 (2  M). Results show the mean   SEM of three experiments. The * and ** denote P   0.05 and P   0.01, respectively, for
experimental vs. wild-type animals, for the parameters indicated.1237 Castrillo et al.
LPS-activated Macrophages from PKC  /  Mice Display
Defects in a Number of Cellular Signaling Pathways. Previous
work has implicated several signaling pathways in the up-
regulation of expression of genes such as NOS-2, TNF ,
and IL-1  after the LPS stimulation of macrophages. Two
such pathways are those involving the ERK1/2 MAP ki-
nases and the family of p38 MAP kinases. The activation of
these kinases was therefore assessed by detection of the
phosphorylated forms of p44ERK, p42ERK, and p38 in
LPS-stimulated macrophage cytosolic extracts. The amount
of phosphorylated p44, p42, and p38 is clearly reduced in
extracts from LPS-stimulated macrophages from PKC  / 
mice, particularly at early time points after stimulation (Fig.
6, A and B). The relevance of this reduction in LPS-
induced p44/p42ERK and p38 activation with respect to
NO synthesis was evaluated. Whereas PD 98059, an inhib-
itor of ERK, was unable to modify NO synthesis in re-
sponse to LPS in macrophages from wild-type animals, SB
203580 and SB 202190, two inhibitors of p38 MAPK, sig-
nificantly inhibited NO synthesis in activated macrophages
from PKC  /  mice (Fig. 6 C), confirming previous data
(26). However, neither SB 203580 nor SB 202190 affected
the already lowered synthesis of NO in PKC  /  mice
(Fig. 6 C). These results suggest that although both the
ERK and p38 MAP kinase signaling cascades are attenuated
in PKC  /  mice in response to LPS, only the p38 MAP
kinase pathway is directly involved in NO production in a
PKC -dependent manner.
PKC  /  Mice Are Less Resistant to Gram-negative and
Gram-positive Bacterial Challenge. As female PKC  / 
mice displayed an unexpected incidence of uterine Gram-
Figure 5. The activation of NF- B and IKK2 are attenuated in LPS-
stimulated macrophages from PKC  /  mice. (A) Thioglycollate-elicited
peritoneal macrophages were activated with 200 ng/ml of LPS, and at the
indicated times cytosolic and nuclear protein extracts were prepared.
NF- B activity was determined by EMSA after the binding of nuclear
proteins to the distal  B sequence of the murine NOS-2 promoter. The
nature of the retained bands was determined by supershift assays (not
shown). Normalization was accomplished using the binding of proteins to
the PPAR  site of acyl CoA oxidase. (B) I B  levels were determined by
Western blot, and the amount of phosphorylated (S32)I B  was evaluated
in cells treated with MG 132 (20  M), and using a specific anti-phos-
pho(S32)-I B  Ab. (C) Macrophages were elicited and treated as above,
and at the indicated time points IKK2 was immunoprecipitated from the
cytosolic extracts. IKK2 activity was assayed using GST-I B  (amino ac-
ids 1–54) and [ -32P]ATP as substrates. Results show the incorporation of
[32P]phosphate into the substrate, with an aliquot of IKK2 assayed by
Western blot to evaluate the level of enzyme.
Figure 6. LPS-mediated signaling events are disrupted in macrophages
from PKC  /  mice. (A and B) Thioglycollate-elicited peritoneal mac-
rophages were activated with 200 ng/ml of LPS, and at the indicated
times cytosolic and nuclear protein extracts were prepared. The levels of
phosphorylated and total p42 ERK and p44 ERK (A), and p38 MAP ki-
nase (B) were determined by Western blot. (C) The effect of p42 and
p44 ERK and p38 MAP kinase on the expression of NOS-2 was deter-
mined measuring the release of nitrite to the culture medium (24 h) in
cells incubated with 50  M PD 98059, an inhibitor of ERK, and 20  M
of SB203580 and SB20190, inhibitors of p38 MAP kinase. Results show
the mean   SEM of three experiments. The * denotes P   0.05 with re-
spect to the LPS (200 ng/ml) and IFN  (20 U/ml) responses in control
vs. experimental animals.1238 Macrophage Activation in PKC  /  Mice
negative bacterial infection, and macrophages from
PKC  /  mice were demonstrated to have a severely at-
tenuated response to LPS stimulation, it was hypothesized
that PKC -deficient animals would be more sensitive to
Gram-negative bacteria than wild-type controls. To assess
this possibility directly, a controlled E. coli bacterial infec-
tion was administered intravenously to both PKC  /  and
wild-type mice. At a bacterial dose of 3   105 pathogens
per gram,  40% of the control animals survived for at least
20 d after infection. In contrast, all PKC  /  mice had died
by day 8 (median; 4.6 and 25.3 d for PKC  /  and wild-
type, respectively; Fig. 7 A). At the higher bacterial dose of
3   106 pathogens per gram, all animals from the wild-type
group had died by day 3. However again, the PKC  / 
mice showed a decreased resistance to infection, as no ani-
mal survived beyond the first day (Fig. 7 B). Interestingly,
when animals were injected with 3   105 Gram-positive S.
aureus per gram of body weight, a difference in survival was
also observed between PKC  /  and wild-type animals
(median; 6.8 and 21 d, respectively; Fig. 7 C). These results
clearly demonstrate that mice deficient for PKC  are more
sensitive to both Gram-negative and Gram-positive bacte-
rial infection than wild-type controls, and that this in-
creased sensitivity to infection can significantly decrease the
likelihood of bacterial clearance and survival.
Discussion
The studies presented here indicate that PKC  plays a
major role in macrophage biology. Although the absence
of PKC  did not seem to influence the differentiation of
monocytes and macrophages from bone marrow precur-
sors, or affect extravasation of macrophages in response to
proinflammatory stimuli, a major defect in the ability of ex-
travased macrophages to respond to LPS was observed. At
low concentrations of LPS (ca. 200 ng/ml) the generation
of NO from PKC  /  macrophages was severely reduced.
The generation of NO, TNF , and IL-1  was also de-
creased after the synergistic activation of PKC  /  macro-
phages with LPS and IFN  (23, 27). Furthermore, several
LPS-activated signaling pathways, involving IKK-2, I B ,
NF B, the ERK MAP kinases, and p38 MAP kinase were
attenuated in PKC -deficient cells. Taken together, these
results suggest that PKC  has a critical function in the regu-
lation of a number of signaling pathways that mediate vari-
ous aspects of macrophage activation.
Macrophages constitute a key component of the innate
immune system, having the ability to recognize relatively
invariant pathogen-associated molecular patterns from a
range of bacteria and fungi (28–31). As a defensive response
to these microbial structures, macrophages can release a di-
verse array of bioactive molecules at sites of infection. These
effector molecules include reactive oxygen and nitrogen
species, prostaglandins, and matrix metalloproteinases (32–
36). Macrophages can also contribute to the initiation of the
adaptive immune response by presenting antigen to T cells
and by expressing costimulatory molecules, such as B7, and
a range of cytokines, such as IL-1 , IL-6, IL-10, and
TNF , that instruct the adaptive immune system about the
general nature of the invading pathogen (28, 35).
LPS is a component of the outer membrane of Gram-
negative bacteria that is recognized as a pathogen-associated
molecular pattern by macrophages (35). The major LPS re-
ceptor complex has been demonstrated to consist of a se-
rum protein known as LPS-binding protein, a GPI-linked
surface protein known as CD14, and the toll-like recep-
tor-4 (TLR-4) transmembrane protein in association with the
product of the MD-2 gene (28, 37–40). The percentage of
Figure 7. PKC  /  mice are more sensitive to Gram-negative and
Gram-positive bacterial challenge. Animals (n   7–11 for each group)
were injected intravenously with either (A) 3   105 or (B) 3   106 E. coli
per gram of body weight, or (C) 3   105 S. aureus per gram of body
weight. Survival of the mice was monitored for up to 20 d. Data were an-
alyzed using the Kaplan-Meier plot. The * denotes P   0.05 for experi-
mental vs. wild-type survival times.1239 Castrillo et al.
macrophages expressing CD14 (and mouse embryonic fi-
broblasts, data not shown) from PKC  /  mice is compara-
ble to that observed in wild-type controls. Furthermore,
the apparent affinity for LPS and anti-CD14 mAbs was also
unaltered on macrophages from PKC -deficient animals
(data not shown). This would imply that PKC  has a role
downstream of the CD14/TLR-4 complex. However, the
defect in LPS-induced macrophage activation in PKC  / 
mice is not as severe as that observed in TLR-4 /  animals,
as some NO generation is observed at low concentrations
of LPS and NO production is comparable to wild-type lev-
els at much higher concentrations of LPS. This would sug-
gest that PKC  is not absolutely essential for LPS-mediated
signaling, but instead could have a modulatory role, ampli-
fying the signaling cascade when levels of LPS are limiting.
The full complement of downstream signaling events
that are initiated by LPS receptor binding are still not fully
understood. However, evidence exists to suggest the in-
volvement of Src-kinases (41), G proteins (42), phospholi-
pase C (43–45), and protein kinase A (46). Several studies
have also implicated MAP kinase activation as a critical
event in LPS-mediated signaling (47–51). We have dem-
onstrated that the extent of both p38 MAP kinase activa-
tion and ERK-1/ERK-2 MAP kinase activation is sig-
nificantly decreased after LPS-stimulation of PKC  / 
macrophages. Furthermore, our results suggest that the
PKC -dependent activation of the p38 MAP kinase path-
way partially induces NO production (26). This would
suggest that the role of PKC  is upstream of phosphoryla-
tion events that activate these kinases, and implicates
PKC  in the activation of a number of diverse signaling
cascades. In this regard, the PKC -mediated activation of
the MAP kinase pathway, leading to the nuclear transloca-
tion of NF B, has recently been demonstrated in adult
rabbit cardiomyocytes (52).
The synthesis of NO has been extensively studied in
macrophages. It is known that NO generation is dependent
on the cellular levels of NOS-2, and that the upregulation
of NOS-2 expression is in turn dependent on NF B bind-
ing at  B sites located in the NOS-2 promoter (25, 53). In
resting cells, NF B forms an inactive complex with the in-
hibitor I B in the cytosol. On activation, the phosphoryla-
tion and degradation of I B by an I B kinase (IKK) results
in the nuclear translocation of NF B and the activation of
target genes (54–57). In RAW 264.7 cells, PKC  expres-
sion was demonstrated to be sufficient for NF B activation
and NOS-2 induction (16). Consistent with these observa-
tions, our data demonstrate that LPS-induced NF B trans-
location and induction of NOS-2 expression are both se-
verely disrupted in macrophages from PKC  /  mice.
Furthermore, I B  phosphorylation and degradation is re-
duced, and IKK-2 activity is significantly decreased in the
absence of PKC .
At present, the signaling events upstream of IKK are not
fully understood, although the involvement of several ki-
nases has been implicated, including NF B-activating ki-
nase (NAK) (58) and TGF -activated kinase (TAK-1) pos-
sibly via the activation of NF B-inducing kinase (NIK)
(59). Interestingly, the expression of a catalytically inactive
NAK protein was shown to specifically inhibit activation of
NF B by PKC , but not by PKC  or PKC  (58). In addi-
tion, this NAK mutant blocked NF B activation by
PDGF, which has been reported to signal through PKC 
(60). However, the authors also reported that although a
dominant negative IKK-2 mutant blocked activation of
NF B by LPS, the catalytically inactive NAK had little ef-
fect. This would suggest that the activation of IKK-2 is
probably mediated by a number of signaling pathways that
may not all be influenced by PKC .
TAK-1 has recently been implicated in a complex sig-
naling cascade from the LPS receptor TLR-4 which in-
volves MyD88, IRAK, TRAF-6, ECSIT, and TAB2
(61–66). It is presently unclear exactly how PKC  could
interact with this pathway. However, it is worth noting
that the TLR-2 receptor-induced signaling cascade has
been shown to share many of these intermediary molecules
(67). As the TLR-2 complex is known to mediate potent
macrophage responses to pathogens such as Gram-positive
bacteria and mycoplasma (68–70), and as PKC  /  mice
displayed an increased sensitivity to Gram-positive bacterial
challenge, it is tempting to speculate that PKC  could
function at a point common to both the TLR-4 and TLR-2
cascades. Further work is underway to establish the basis of
the increased sensitivity to Gram-positive bacteria observed
in this study.
The synthesis of LPS-induced proinflammatory media-
tors such as NO, TNF , and IL-1  are required for the full
activation of macrophage function and the correct initia-
tion of an appropriate immune response to a Gram-nega-
tive bacterial infection (28, 35, 71–73). Our results clearly
demonstrate that in mice lacking PKC  the generation of
LPS-induced proinflammatory mediators is notably dimin-
ished. This would predict that PKC  /  mice would be
sensitive to infection by Gram-negative bacteria such as E.
coli. Consistent with this hypothesis, we observed a fre-
quent incidence of E. coli infection in the uteri of PKC  / 
animals, a type of infection that was never observed in con-
trol animals over a similar period. Furthermore, in a con-
trolled intravenous infection of animals with E. coli, sur-
vival times were markedly reduced in the absence of
PKC . However, we also observed a decreased macro-
phage response to IFN  challenge, and an increased sensi-
tivity to Gram-positive bacteria in PKC -deficient animals.
Taken together, these data conclude that PKC  is a critical
mediator of several signaling cascades in activated macro-
phages, and that in the absence of PKC , the successful ini-
tiation of an effective immune response against a range of
bacterial pathogen is severely compromised.
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